drugset / Trial / NCT05561023
Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerance of Hawthorn red pigment in the treatment of cancer pain Determine the maximum tolerated dose (MTD, if any) of Hawthorn red pigment and the recommended dose for phase II clinical study (RP2D)
Timeline
- Start
- 2022-10-01
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hawthorn red pigment | Unknown | 10 unknown | Oral |
| Subject | Hawthorn red pigment | Unknown | 15 unknown | Oral |
| Subject | Hawthorn red pigment | Unknown | 20 unknown | Oral |
Indications
No indication recorded.